Astellas Jobs and Investments- Tralee
Established: Astellas was formed in 2005 after the merger of Yamanouchi Pharmaceutical Co., Ltd. and the Fujisawa Pharmaceutical Co., Ltd. The facility in Mulhuddart, Dublin was established (originally as Yamanouchi) in 1986 as a manufacturing plant for Active Pharmaceutical Ingredients for medicinal products, with production operations commencing in 1988. Astellas currently uses approx one third of its 50-acre Dublin site for production and related activities with the remainder of the land being available for future development and site expansion. Today, the bulk active pharmaceutical ingredients manufactured on the site include Mirabegron, Solifenacin and Tamsulosin used in the treatment of overactive bladder and prostate gland disorder.
Astellas has a second manufacturing plant in Killorglin, Kerry which was established in 1990 (originally as Fujisawa) and manufactures a range of treatments, including the immunosuppressant Prograf® which is supplied globally from Killorglin.
Astellas Tralee
Jobs and Investment: Astellas Pharma Inc. announced in September 2023 its intention to submit a planning application to build a new state-of-the-art facility, at an approximate cost of €330 million in Tralee, Co. Kerry. This investment will expand their capacity and capabilities for aseptic drug products, reinforce stable production for global supply and accelerate the development and commercialisation of innovative antibody drugs and other new products. The facility will be based on the IDA greenfield site in Kerry Technology Park, Tralee, bringing highly specialised engineering, science and technology roles to the region. Construction will commence in April 2024, with the site expected to be operational by 2028.